MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 5, 2012, Pages 663-668

  Bhattacharjee, Alpana ^a   Allister, Emma M ^a   Wheeler, Michael B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

cell; Dipeptidyl peptidase 4 (DPP 4) inhibitor; Glucagon; Glucose tolerance; Insulin; MK 626; MKR mice; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCOSE; METHYLCELLULOSE; MK 626; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON; GLUCOSE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HYPERGLYCEMIA; HYPERINSULINISM; INCRETINS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, OBESE; PHENYLALANINE; TRIAZOLES;

EID: 84860805074     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-039     Document Type: Article

References (20)

1. Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., and Williams-Herman, D.E. Sitagliptin Study 021 Group. 2006. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 29(12): 2632-2637. doi:10.2337/dc06-0703. PMID:17130196.
2. Asghar, Z., Yau, D., Chan, F., Leroith, D., Chan, C.B., and Wheeler, M.B. 2006. Insulin resistance causes increased b-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia, 49(1): 90-99. doi:10.1007/s00125005-0045-y. PMID:16362284.
3. Cook, M.N., Girman, C.J., Stein, P.P., and Alexander, C.M. 2007. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. 24(4): 350-358. doi:10.1111/j.1464-5491.2007.02078.x. PMID: 17335466.
4. Edmondson, S.D., Mastracchio, A., Mathvink, R.J., He, J., Harper, B., Park, Y.J., et al. 2006. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6ylphenyl)butanamide: a selective a-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 49(12): 3614-3627. doi:10.1021/jm060015t. PMID: 16759103.
5. Fernandez, A.M., Kim, J.K., Yakar, S., Dupont, J., Hernandez-Sanchez, C., Castle, A.L., et al. 2001. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15(15): 1926-1934. doi:10.1101/gad. 908001. PMID:11485987.
6. Goldstein, B.J., Gomis, R., Lee, H.K., and Leiter, L.A. 2007. Type 2 diabetes-treat early, treat intensively. Int. J. Clin. Pract. Suppl. 61(Suppl. S157): 16-21. doi:10.1111/j.1742-1241.2007.01610.x.
7. Herman, G.A., Stevens, C., Van Dyck, K., Bergman, A., Yi, B., De Smet, M., et al. 2005. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebocontrolled studies with single oral doses. Clin. Pharmacol. Ther. 78(6): 675-688. doi:10.1016/j.clpt.2005.09.002. PMID:16338283.
8. Herman, G.A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., et al. 2006. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91(11): 4612-4619. doi:10.1210/jc. 2006-1009. PMID:16912128.
9. Heron-Milhavet, L., Haluzik, M., Yakar, S., Gavrilova, O., Pack, S., Jou, W.C., et al. 2004. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology, 145(10): 4667-4676. doi:10.1210/en.2003-1543. PMID:15231693.
10. Kim, E.J., Park, K.S., Chung, S.Y., Sheen, Y.Y., Moon, D.C., Song, Y.S., et al. 2003. Peroxisome proliferator-activated receptor-g activator 15-deoxy-d12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J. Pharmacol. Exp. Ther. 307(2): 505-517. doi:10.1124/jpet.103.053876. PMID: 12966153.
11. Krentz, A.J., and Bailey, C.J. 2005. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 65(3): 385-411. doi:10.2165/00003495-200565030-00005. PMID:15669880.
12. Lu, H., Yang, Y., Allister, E.M., Wijesekara, N., and Wheeler, M.B. 2008. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. Mol. Cell. Proteomics, 7(8): 1434-1451. doi:10.1074/ mcp.M700478-MCP200. PMID:18448419.
13. Lu, H., Koshkin, V., Allister, E.M., Gyulkhandanyan, A.V., and Wheeler, M.B. 2010. Molecular and metabolic evidence for mitochondrial defects associated with b-cell dysfunction in a mouse model of type 2 diabetes. Diabetes, 59(2): 448-459. doi:10. 2337/db09-0129. PMID:19903739.
14. McIntosh, C.H. 2008. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front. Biosci. 13(13): 1753-1773. doi:10.2741/2797.PMID:17981665.
15. McIntosh, C.H., Widenmaier, S., and Kim, S.J. 2010. Pleiotropic actions of the incretin hormones. Vitam. Horm. 84: 21-79. doi:10.1016/B978-0-12-381517-0.00002-3. PMID:21094896.
16. Mu, J., Woods, J., Zhou, Y.P., Roy, R.S., Li, Z., Zycband, E., et al. 2006. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell mass and function in a rodent model of type 2 diabetes. Diabetes, 55(6): 1695-1704. doi:10.2337/db05-1602. PMID:16731832.
17. Mu, J., Petrov, A., Eiermann, G.J., Woods, J., Zhou, Y.P., Li, Z., et al. 2009. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol. 623(1-3): 148-154. doi:10. 1016/j.ejphar.2009.09.027. PMID:19765579.
18. Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., and Khatami, H. Sitagliptin Study 023 Group. 2006. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 49(11): 2564-2571. doi:10.1007/s00125-006-0416-z. PMID:17001471.
19. Toyoshima, Y., Gavrilova, O., Yakar, S., Jou, W., Pack, S., Asghar, Z., et al. 2005. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology, 146(9): 4024-4035. doi:10.1210/en.2005-0087. PMID:15947005.
20. Turner, R.C., Cull, C.A., Frighi, V., and Holman, R.R. UK Prospective Diabetes Study (UKPDS) Group. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA, 281(21): 2005-2012. doi:10.1001/jama.281.21. 2005. PMID:10359389.